REG - GSK PLC - Jemperli receives US FDA breakthrough designation

GSKAnnouncement

16/12/2024 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241216:nRSP1957Qa&default-theme=true

RNS Number : 1957Q  GSK PLC  16 December 2024

Issued: 16 December 2024, London UK

 

Jemperli (dostarlimab) receives US FDA Breakthrough Therapy Designation for
locally advanced dMMR/MSI-H rectal cancer

 

·   Designation based on data showing no evidence of disease in 100% of all
42 patients who completed treatment with dostarlimab

·   Breakthrough Therapy Designation granted to drugs with potential to show
improvement over available therapies for serious conditions

 

·   Current standard of care can be associated with significant negative
quality-of-life effects, highlighting the need for new options

 

 

GSK plc (LSE/NYSE: GSK) announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Jemperli (dostarlimab) for the treatment of patients with locally advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) rectal cancer. The Breakthrough Therapy Designation aims to expedite the development and review of drugs with the potential to treat a serious condition and where preliminary clinical evidence may indicate substantial improvement over currently available therapy.
 1  (#_edn1)
 This is the second regulatory designation for dostarlimab in locally advanced dMMR/MSI-H rectal cancer, following Fast Track designation for the same patient population in January 2023.
[2 (#_edn2)

 Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: "Today's designation, which is based on the unprecedented 100% clinical complete response rate of dostarlimab reported to date, supports a path to help change the treatment paradigm for patients with locally advanced dMMR/MSI-H rectal cancer, who face long-term adverse quality-of-life effects. Our registrational AZUR-1 trial is continuing to study dostarlimab in this patient population."

 

The US FDA's Breakthrough Therapy Designation is supported by preliminary
clinical evidence from the ongoing phase II GSK supported collaborative study
with Memorial Sloan Kettering Cancer Center. In frontline locally advanced
dMMR rectal cancer, the trial has shown an unprecedented 100% clinical
complete response (cCR) in all 42 patients who completed treatment with
dostarlimab, defined as no evidence of tumours as assessed by magnetic
resonance imaging, endoscopy, PET scan and digital rectal exam. In the first
24 patients evaluated, a sustained cCR with a median follow-up of 26.3 months
(95% CI: 12.4-50.5) was observed. The safety and tolerability profile of
dostarlimab was generally consistent with the known safety profile of the
agent. No adverse events of grade 3 or higher were reported in this trial. 3 
(#_edn3) The trial continues to evaluate enrolled patients. GSK's ongoing
phase II registrational AZUR-1 trial in locally advanced dMMR/MSI-H rectal
cancer aims to confirm the findings of this supported collaborative study.

 

The current standard of care for patients with dMMR/MSI-H locally advanced
rectal cancer is initial treatment with chemotherapy plus radiation followed
by surgery to remove the tumour along with portions of the intestine and/or
surrounding tissue. 4  (#_edn4) This results in initial positive outcomes for
most patients, but nearly one-third ultimately die from cancer that has spread
to other parts of the body (distant metastasis). 5  (#_edn5) Additionally, the
surgery and chemoradiotherapy associated with standard of care can lead to
long-term negative impact on quality-of-life, including bowel, urinary and
sexual dysfunction, secondary cancers and infertility.(2)

 

Dostarlimab is not approved anywhere in the world for the frontline treatment of locally advanced dMMR/MSI-H rectal cancer.
About dMMR/MSI-H rectal cancer

Rectal cancer is a form of cancer that starts in the rectum, the final section of the large intestine, and is often categorised as part of a group of cancers called colorectal cancer. Colorectal cancer is the third most commonly diagnosed cancer in the world.
 6  (#_edn6)
 In the US, it is estimated that approximately 46,220 individuals are diagnosed annually with rectal cancer.
 7  (#_edn7)
 Approximately 5-10% of all rectal cancers are dMMR/MSI-H, meaning that they contain abnormalities that affect the proper repair of DNA when copied in a cell.
 8  (#_edn8)
 Mismatch repair deficient status is a biomarker that has been shown to predict response to immune checkpoint blockade with PD-1 therapy.
 9  (#_edn9)
(,)
 10  (#_edn10)
 Tumours with this biomarker are most commonly found in endometrial, colorectal and other gastrointestinal cancers but may also be found in other solid tumours.
 11  (#_edn11)
(-14)
 12  (#_edn12)

 13  (#_edn13)

 14  (#_edn14)

About Jemperli (dostarlimab) 
 Jemperli, a programmed death receptor-1 (PD-1)-blocking antibody, is the backbone of GSK's ongoing immuno-oncology-based research and development programme. A robust clinical trial programme includes studies of Jemperli alone and in combination with other therapies in gynaecologic, colorectal and lung cancers, as well as where there are opportunities for transformational outcomes.

 In the US, Jemperli is indicated in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer. This includes patients with mismatch repair proficient/microsatellite stable (MMRp/MSS) and dMMR/MSI-H tumours. Jemperli is also approved as a single agent for adult patients with dMMR recurrent or advanced endometrial cancer, as determined by a US FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. Additionally, Jemperli is indicated in the US for patients with dMMR recurrent or advanced solid tumours, as determined by a US FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. The latter indication is approved in the US under accelerated approval based on tumour response rate and durability of response. Continued approval for this indication in solid tumours may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Jemperli was discovered by AnaptysBio, Inc. and licensed to TESARO, Inc., under a collaboration and exclusive license agreement signed in March 2014. Under this agreement, GSK is responsible for the ongoing research, development, commercialisation, and manufacturing of Jemperli and cobolimab (GSK4069889), a TIM-3 antagonist. 

Important Information for Jemperli in the EU
 Jemperli is indicated:

·      in combination with carboplatin and paclitaxel, for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy;

·      as monotherapy for treating adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.

Refer to the Jemperli EMA Reference Information for a full list of adverse events and the complete important safety information in the EU here: https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli.

 

GSK in oncology
Oncology is an emerging therapeutic area for GSK where we are committed to
maximising patient survival with a current focus on haematologic malignancies,
gynaecologic cancers, and other solid tumours through breakthroughs in
immuno-oncology and tumour-cell targeting therapies.

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Tim Foley                   +44 (0) 20 8047 5502  (London)
                      Dan Smith / Madison Goring  +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn              +1 202 603 5003       (Washington DC)
                      Lyndsay Meyer               +1 202 302 4595       (Washington DC)

 Investor Relations:  Annabel Brownrigg-Gleeson   +44 (0) 7901 101944   (London)
                      James Dodwell               +44 (0) 7881 269066   (London)
                      Mick Readey                 +44 (0) 7990 339653   (London)
                      Camilla Campbell            +44 (0) 7803 050238   (London)
                      Steph Mountifield           +44 (0) 7796 707505   (London)
                      Jeff McLaughlin             +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco            +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q3 Results for 2024.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

(#_ednref1) References

 

 1  US Food and Drug Administration. Breakthrough Therapy. Available at:
https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy

 2  (#_ednref2)
https://www.gsk.com/en-gb/media/press-releases/us-fda-advisory-committee-votes-in-support-of-trials-designed-to-evaluate-jemperli-dostarlimab-gxly-as-a-potential-treatment-for-dmmrmsi-h-locally-advanced-rectal-cancer/

 3  (#_ednref3)
https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-trial-continues-to-show-unprecedented-results/

 4  (#_ednref4) Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in
mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;
386: 2363-76.

 5  (#_ednref5) Smith JJ, et al. Rectal Cancer Consortium. Organ Preservation
in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating
3-year disease-free survival in patients with locally advanced rectal cancer
treated with chemoradiation plus induction or consolidation chemotherapy, and
total mesorectal excision or nonoperative management. BMC Cancer. 2015 Oct
23;15:767. doi: 10.1186/s12885-015-1632-z. PMID: 26497495; PMCID: PMC4619249.

 6  (#_ednref6) Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics
2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers
in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
doi:10.3322/caac.21660.

 7  (#_ednref7) Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA
Cancer J Clin. 2024;74(1):12-49. doi:10.3322/caac.21820

 8  (#_ednref8) Cercek A, et al. Mismatch Repair-Deficient Rectal Cancer and
Resistance to Neoadjuvant Chemotherapy. Clin Cancer Res. 2020 Jul
1;26(13):3271-3279. doi: 1158/1078-0432.CCR-19-3728. Epub 2020 Mar 6. PMID:
32144135; PMCID: PMC7348681.

 9  (#_ednref9) Le DT, et al. PD-1 blockade in tumors with mismatch repair
deficiency. N Engl J Med. 2015;372(26):2509-2520.

 10  (#_ednref10) Andre T, Berton D, Curigliano G, et al. Antitumor Activity
and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair
Deficient Solid Tumors: A Nonrandomized Controlled Trial. JAMA Netw Open.
2023;6(11):e2341165. doi:10.1001/jamanetworkopen.2023.41165

 11  (#_ednref11) National Cancer Institute at the National Institutes of
Health. Definition of mismatch repair deficiency. Accessed April 19, 2024.
Available at:
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/mismatch-repair-deficiency.

 12  (#_ednref12) Lorenzi M, et al. Epidemiology of microsatellite instability
high (MSI-H) and deficient mismatch repair (dMMR) in solid tumors: a
structured literature review. J Oncol. 2020. doi.org/10.1155/2020/1807929.

 13  (#_ednref13) Zhao P, et al. Mismatch repair deficiency/microsatellite
instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J
Hematol Oncol. 2019;12(1):54. doi: 10.1186/s13045-019-0738-1.

 14  (#_ednref14) Laken H, Kehry M, Mcneeley P, et al. Identification and
characterization of TSR-042, a novel anti-human PD-1 therapeutic antibody.
European Journal of Cancer. 2016;69, S102. doi:10.1016/s0959-8049(16)32902-1.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDXBDDRBBDGSU